Compass Pathways provides further details on its Phase IIb results for the treatment of Treatment Resistant Depression, including reporting of additional "patient improvements".
Novamind expands its treatment footprint via a new partnership with Uruguay-based Bienstar Wellness.
atai Life Sciences adds to its holding in Compass Pathways, raising its ownership interest back to 20.8%.
Seelos Therapeutics announces $20 million in new funding via convertible note, with an option for an additional $30 million.
The 5th USPTO patent for Compass Pathways covers methods of treating depression with crystalline psilocybin.
The program aims to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States.
Psychedelic medicine is both extremely efficacious and highly cost-effective. It is also an absolute necessity to RESCUE the economy.
Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues.